{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T15:29:28Z","timestamp":1793806168814,"version":"4.6.1"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"39","license":[{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9,25]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Ovarian cancer is one of the most lethal gynecological malignancies globally, with significant variations in incidence, prevalence, and outcomes across regions and population subgroups. This study systematically evaluates the global, regional, and national burden of ovarian cancer from 1990 to 2021, utilizing data from the Global Burden of Disease 2021 framework. Trends in incidence, prevalence, mortality, and disability-adjusted life years were analyzed, with an emphasis on their associations with the Socio-Demographic Index (SDI) and other key risk factors. The analysis highlights substantial disparities in ovarian cancer burden, with low- and middle-SDI regions experiencing the highest mortality-to-incidence ratios. In 2021, ovarian cancer accounted for approximately 298,876 new cases globally, with age-standardized incidence rates declining in high-SDI regions but increasing in low-SDI regions. Mortality trends mirrored this pattern, with significant disparities between high- and low-resource settings. The findings underscore the critical influence of age, genetics, and access to early detection and treatment. Forecasts using an ARIMA model indicate a continued rise in the global burden, particularly in regions with limited healthcare resources. This study underscores the urgent need for targeted interventions to improve ovarian cancer outcomes, including enhanced screening, equitable access to treatment, and strategies addressing modifiable risk factors, particularly in underserved regions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000050828","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T18:00:59Z","timestamp":1790359259000},"page":"e50828","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Global, regional, and national burden of ovarian cancer from 1990 to 2021"],"prefix":"10.1097","volume":"105","author":[{"given":"Chaokang","family":"Huang","sequence":"first","affiliation":[{"name":"Department of Pathology, Xingtai Peoples Hospital, Hebei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Pathology, Xingtai Peoples Hospital, Hebei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pathology, Xingtai Peoples Hospital, Hebei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xike","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pathology, Xingtai Peoples Hospital, Hebei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Xingtai Peoples Hospital, Hebei, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-20261104","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.molonc.2009.02.001","article-title":"The contribution of BRCA1 and BRCA2 to ovarian cancer.","volume":"3","author":"Ramus","year":"2009","journal-title":"Mol Oncol"},{"key":"R3-20261104","doi-asserted-by":"crossref","first-page":"77","DOI":"10.6004\/jnccn.2021.0001","article-title":"Genetic\/familial high-risk assessment: breast, ovarian, and pancreatic, version 2.2021, NCCN clinical practice guidelines in oncology.","volume":"19","author":"Daly","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"R4-20261104","doi-asserted-by":"crossref","first-page":"9","DOI":"10.20892\/j.issn.2095-3941.2016.0084","article-title":"Epidemiology of ovarian cancer: a review.","volume":"14","author":"Reid","year":"2017","journal-title":"Cancer Biol Med"},{"key":"R5-20261104","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1093\/jnci\/djt065","article-title":"Disparities in ovarian cancer care quality and survival according to race and socioeconomic status.","volume":"105","author":"Bristow","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"R6-20261104","doi-asserted-by":"crossref","first-page":"100458","DOI":"10.1016\/j.jcpo.2023.100458","article-title":"Where are the inequalities in ovarian cancer care in a country with universal healthcare? A systematic review and narrative synthesis.","volume":"39","author":"Pickwell-Smith","year":"2024","journal-title":"J Cancer Policy"},{"key":"R10-20261104","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/JS9.0000000000003398","article-title":"Global, regional, and national burden of ovarian cancer, 1990-2021, and projections to 2050: a cross-sectional analysis of the Global Burden of Disease Study 2021.","volume":"112","author":"Xie","year":"2026","journal-title":"Int J Surg"},{"key":"R11-20261104","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(08)60167-1","article-title":"Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls.","volume":"371","author":"Beral","year":"2008","journal-title":"Lancet"},{"key":"R12-20261104","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R13-20261104","first-page":"284","article-title":"Ovarian cancer statistics, 2018.","volume":"68","author":"Torre","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"R14-20261104","doi-asserted-by":"crossref","first-page":"vi24","DOI":"10.1093\/annonc\/mdt333","article-title":"Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.","volume":"24","author":"Ledermann","year":"2013","journal-title":"Ann Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050828","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T15:00:47Z","timestamp":1793804447000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050828"}},"subtitle":["Analysis of risk factors and prediction of trends in 2050"],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":10,"journal-issue":{"issue":"39","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000050828","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,25]]},"assertion":[{"value":"2025-10-17","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-11","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}